J&J, Schwab and midweek earnings

Jim discusses J&J's pharma spin, talc litigation, Charles Schwab's asset inflows and beneficiaries of baby-boomer wealth transfer.

Play episode from 04:22

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!